GEN Exclusives

More »

GEN News Highlights

More »
Jan 10, 2012

Aeras and China National Biotec Partner for Better Global TB Vaccines

  • Aeras, a nonprofit organization dedicated to developing tuberculosis (TB) vaccines and biologics, is partnering with China National Biotec Group (CNBG) on a program centered on new TB vaccines. The partnership will involve multiple research institutes that operate under CNBG working with Aeras to develop, manufacture, and distribute affordable TB vaccines for use globally.

    Through the deal Aeras will license its recombinant BCG (rBCG) platform and other technologies to CNBG, and the collaborators will use the platform, in combination with other technologies provided by both partners, to develop more effective an longer-lasting TB vaccine candidates.

    “The synergy created by bringing together our scientific and manufacturing expertise could have a substantial impact on efforts to advance innovative candidates in TB vaccine development,” comments Jim Connolly, Aeras president and CEO. “We look forward to working with the largest biotech corporation in the country with the skills, resources, and TB disease burden to play a major role in overcoming the complex challenges of TB vaccine R&D." 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?